Clinical Trials Logo

Follicular Lymphoma Grade 3A clinical trials

View clinical trials related to Follicular Lymphoma Grade 3A.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02710643 Completed - Clinical trials for Follicular Lymphoma, Grade 1

"MIRO" Molecularly Oriented Immuno-radio-therapy

FIL_MIRO
Start date: October 2014
Phase: Phase 2
Study type: Interventional

Phase II prospective multicenter study for stage I/II Follicular Lymphoma treated with involved-field radiotherapy (IFRT) at doses of 24 Gy) with or without Ofatumumab for 8 weekly doses on molecular basis. Patients with positive basal Bcl-2 will be followed every 3 months and with Bcl-2 detection every 6 months for 3 years. Patient with negative basal Bcl-2 will be followed every 3 months without further Bcl-2 detection. Ofatumumab treatment will be administered to: 1. Patients with positive basal PCR for Bcl-2-IgH rearrangement in BM and/or PB, resulting still positive after IFRT; 2. Patients with positive basal PCR for Bcl-2-IgH in